Research & Development
Publications & Presentations
Disclaimer
Etripamil remains under clinical investigation as a potential treatment for rapid heart rates associated with atrial fibrillation and is not approved in the United States or anywhere else in the world for this indication. The publications in this section are for educational purposes to discuss clinical data relating to etripamil.
Phase 2
Randomized Controlled Trial
A Multicenter, Phase 2, Randomized, Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)
Circulation: Arrhythmia and Electrophysiology (Nov 2023)
A Multicenter, Placebo-Controlled, Phase 3 Study of Etripamil in Patients With Atrial Fibrillation and Rapid Ventricular Rate: ReVeRA-301 Trial Design
Atrial Fibrillation Symposium (Jan 2025)
Etripamil Use in Atrial Fibrillation With Rapid Ventricular Rate
Western Atrial Fibrillation Symposium (Feb 2024)
Concomitant Antiarrhythmic Use Among Patients Who Received Etripamil for Atrial Fibrillation With Rapid Ventricular Rate
Western Atrial Fibrillation Symposium (Feb 2024)
Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Atrial Fibrillation: Phase 2 ReVeRA-201
Cardiovascular Clinical Trialists (Nov 2023)
Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Atrial Fibrillation: Phase 2 ReVeRa-201
American Heart Association (Nov 2023)
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
Heart Rhythm Society (May 2023)
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
Heart Rhythm Society (May 2023)
.png){kind=small}